California Emerging Infections Program (CEIP) MPOX Vaccine Effectiveness Study 2022-2024





Overview

CEIP

The Role of Partnerships

MPOX Outbreak

VE Study



California Emerging Infections Program (CEIP)




California Emerging Infections Program(CEIP)

CDC's Division of Preparedness and Emerging Infections

10 EIP Sites

CEIP





2022 MPOX Outbreak

32, 063 cases nationally

~ 6, 192 cases in California

~ GBMSM and HIV communities @ risk



Overview



Study implemented in 2022, ongoing in 2024



GOAL: Evaluate JYNNEOS vaccine effectiveness



12 EIP sites

CEIP catchment area

Alameda, Contra Costa, San Francisco



Objectives

Primary Objective • Estimate the effectiveness of JYNNEOS MPX vaccine in preventing MPX infection among at risk communities.

Secondary Objective

- Estimate vaccine effectiveness by other factors of public health importance:
 - Route of administration
 - Number of doses
 - Timing of doses
 - Age groups
 - Immunocompromised status
 - Clinical endpoints

Participation Requirements

Sexually active persons aged 18-49 years who self-identify as MSM or transgender.

Cases who had a probable *Monkeypox virus* or *Orthopoxvirus diagnosis* on or after August 19, 2022.

Controls who had a sexual health, HIV care, or HIV PrEP clinic visit on or after August 19, 2022 (with no previous mpox diagnosis).

Residents of CEIP's catchment area which includes Alameda, Contra Costa, and San Francisco counties at the time of diagnosis/clinic visit.



Study Process

Recruitment

- Cases received from CDPH
- Controls identified through Qualtrics Eligibility Screening Form (HIPAA compliant)

Enrollment

- Max 5 contact attempts
- Study consent through DocuSign

Data Collection & Survey Wrap Up

- Phone interview
- REDCap
- Data is de-identified
- Gift Card Sent



The Role of Partners



Where we need YOUR help

Recruitment

Cases received from CDPH

Controls identified through Qualtrics Eligibility Screening Form (HIPAA compliant)

Enrollment

- Max 5 contact attempts
- Study consent through DocuSign

Data Collection & Survey Wrap Up

- Phone interview
- REDCap
- Data is de-identified
- Gift Card Sent



Control Recruitment Strategies

Newsletters & Email blasts


Social Media

Posters

Provide patient list to CEIP



Study Material



*Receiving HIV PrEP is not a requirement for eligibility CEIP Principal Investigators Anita Ogayemi-Agoh 510.406.0914 (email) aoagoh@ceip.us





CEIP Team

Project Coordinator: Anita Ogayemi-Agoh

Email aoagoh@ceip.us

Phone (510)406-0914

Associate Director: Gretchen Rothrock

Program Manager: Joelle Nadle

Research Assistants: Madeline Anderson

Vanessa Anguiano

Irma Parada

